1604. Cost-Effectiveness of Ceftazidime-Avibactam for Patients with Hospital-Acquired Pneumonia Caused by Multi-Drug Resistant Enterobacteriaceae or Pseudomonas in China

BACKGROUND: To estimate the cost-effectiveness of ceftazidime-avibactam (CAZ-AVI) for the treatment of hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) caused by multi-drug resistant enterobacteriaceae (MDRE) or MDR pseudomonas aeruginosa (MDRPA) in China. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Furnback, Wesley, Chen, YiXi, Dong, Peng, Wang, Bruce, Ansari, Wajeeha, Charbonneau, Claudie, Dong, Hengjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776513/
http://dx.doi.org/10.1093/ofid/ofaa439.1784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776513/
http://dx.doi.org/10.1093/ofid/ofaa439.1784

Ejemplares similares